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Diabetic mellitus (DM) patients with coronary artery disease (CAD) are at higher risk of cardiovascular events compared with non-DM
individuals. While aggressive cardiovascular prevention and adequate blood glucose control remain cornerstones of therapy, the decision
when and how to proceed to coronary revascularization in an individual DM patient should be based on the extent of CAD, ischaemic
burden, ventricular function, as well as comorbidities. While in patients with stable symptoms, moderate CAD on coronary angiography
and preserved left ventricular function a conservative strategy may be a valuable initial strategy, in patients with acute coronary syndromes
(ACS) an early invasive approach should be favoured. The revascularization strategy for DM patients with complex multivessel CAD should
be discussed within a heart team consisting of cardiologists, cardiac surgeons, and anaesthesiologists. In general, the threshold for coronary
artery bypass surgery (CABG) should be lower for DM than for non-DM individuals. In patients undergoing percutaneous coronary inter-
vention, the use of drug-eluting stents (DES) and—in the setting of ACS—of potent platelet inhibitors, such as prasugrel or ticagrelor, should
be favoured. In the near future, multiple strategies may further favourably impact the prognosis of DM patients undergoing coronary revas-
cularization. These include alternative antiplatelet agents such as thromboxane receptor inhibitors, the broad use of second generation DES,
and possibly the implantation of bioresorbable stents. Coronary artery bypass surgery outcomes may also further improve by wide
implementation of arterial revascularization, reduction in perioperative stroke by avoiding clamping of the aorta, reduction in wound infec-
tion by minimally invasive techniques, and optimization of post-operative medical management.
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Introduction
Diabetes mellitus (DM) is a metabolic condition characterized by
dysfunction in insulin secretion and insulin action resulting in
chronic hyperglycaemia and deeply affecting the cardiovascular
system. In the last few decades, the prevalence of DM has
assumed epidemic proportion in Western countries and is
expected to follow a similar pattern in the developing world. It
has been estimated that the global prevalence of DM among
adults will be 6.4% (285 million individuals) in 2010 and 7.7%
(439 million individuals) in 2030.1 In the USA, the costs related
to DM have been estimated at $172 billion in 2007—$116
billion for direct and $58 billion for indirect medical costs such
as disability and work loss—while they are expected to rise to
$192 billion by 2020.2
An example of the deleterious impact of DM on cardiovascular
prognosis was illustrated in a Danish population-based study on 3.3
million people showing that DM patients without a history of cor-
onary artery disease (CAD) had the same 5-year cardiovascular
mortality as non-DM patients with a history of myocardial infarc-
tion (MI).3 Additional cardiovascular risk factors and comorbidities
that negatively impact cardiovascular outcomes are more prevalent
in DM patients.4 However, DM itself is the main cause of acceler-
ated atherogenesis and atherothrombosis observed in this patient
population.5 In Western countries, up to one-fourth of all coron-
ary revascularization procedures—either coronary artery bypass
grafting (CABG) or percutaneous coronary intervention (PCI)—
may involve DM patients. Until recently, comparative data
between PCI and CABG in DM were limited to subgroup analyses
of randomized trials, while the evidence in favour of myocardial
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revascularization over medical management was even sparser.
Now, the results of randomized trials including sizable populations
of DM patients are available both on myocardial revascularization
in stable and unstable patients and on drug-eluting stent (DES)-
based PCI vs. CABG in multivessel CAD.
Diabetes-associated
atherothrombosis
Prothrombotic and proinflammatory states, in adjunct to endo-
thelial dysfunction and metabolic disorders, such as hyperglycae-
mia, dyslipidaemia, obesity, insulin resistance, and oxidative
stress, are key features of the accelerated atherosclerotic
process observed in patients with DM.5,6 The prothrombotic
status is the consequence of multiple conditions, including
increased platelet reactivity; increased levels of procoagulant
agents such as fibrinogen, tissue factor, von Willebrand factor,
platelet factor 4, factor VII; decreased concentrations of endogen-
ous anticoagulants including protein C and antithrombin III; and
impaired endogenous fibrinolysis secondary to elevated levels of
plasminogen activator inhibitor-1.7
As described in Figure 1, multiple mechanisms contribute to
increased platelet aggregation in DM patients. First, hyperglycaemia
may induce the expression of the surface adhesion molecule P-
selectin, the glycation of platelet surface proteins with consequent
membrane fluidity decrease and platelet adhesion increase, the
activation of protein kinase C, and may exert a direct osmotic
effect.7 Hyperglycaemia may also promote atherothrombosis via
oxidation of amino groups, formation of advanced glycation end-
products, endothelial dysfunction, subendothelial cellular prolifer-
ation, and increased matrix expression.8 Other abnormalities that
contribute to the enhanced platelet adhesion and activation in
DM include the increased expression of the platelet receptor gly-
coprotein (GP) IIb/IIIa, up-regulation of platelet P2Y12 receptor sig-
nalling, increased platelet turnover, and enhanced oxidative stress.7
Finally, insulin resistance may increase intracellular calcium concen-
tration and impair the response to nitric oxide.
Additional metabolic conditions that may enhance platelet reac-
tivity include obesity (via insulin resistance, augmented cytosolic
calcium concentration, and increased oxidative stress), dyslipidae-
mia, systemic inflammation, and endothelial dysfunction. The
latter, a characteristic feature of DM, is mediated by
Figure 1 Mechanisms involved in platelet dysfunction and prothrombotic status in diabetes mellitus patients. ADP, adenosine diphosphate;
CA++, calcium; GP, glycoprotein; IRS, insulin receptor substrate; NO, nitric oxide; PGI2, prostacycline; PKC, protein kinase C; ROS/NOS, reac-
tive oxygen and nitrogen species; TF, tissue factor; H2O, water. Adapted with permission from Ferreiro and Angiolillo.
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hyperglycaemia, increased free fatty acid production, altered lipo-
proteins, insulin resistance, and hypertension.5
Percutaneous coronary
interventions
Impact of drug-eluting stents
The main limitation of bare metal stents (BMS)-based PCI, and
more so in DM patients, is restenosis. A meta-analysis of six
BMS trials, including 1166 DM and 5070 non-DM patients,
detected a restenosis rate of 37% in DM patients and identified
DM as an independent predictor of restenosis [odds ratio (OR)
1.3].9 Even in the DES era, DM patients undergoing PCI have
worse outcomes compared with non-DM individuals. The EVAS-
TENT registry enrolled 1731 patients undergoing DES implantation
and followed them for a median of 465 days. For each DM patient
(stratified as single- or multivessel disease), a non-DM one was
subsequently enrolled.10 The highest major adverse cardiac event
(MACE) rate was observed among DM patients with multivessel
disease while DM patients with single vessel disease had similar
event rates than non-DM individuals with multivessel disease. In
addition, DM patients—especially those treated with insulin—
had higher mortality as well as stent thrombosis and target
vessel revascularization (TVR) rates at 1 year.
Of note, the initial randomized DES investigation in DM patients
was troubled by the results of a subgroup analysis of four
sirolimus-eluting stents vs. BMS trials including a total of 428 DM
patients reporting a statistically significant increase in cardiovascu-
lar mortality that persisted at 5 years in patients allocated to DES
compared with those treated with BMS.11 However, subsequent
adequately powered studies could not confirm the findings of a
harmful effect of DES in DM patients. Accordingly, a network
meta-analysis of 35 randomized trials comparing DES with BMS
and including 3852 DM patients showed that the use of DES,
while not affecting overall mortality or MI rates, was associated
with a 60–70% relative risk (RR) reduction in target lesion revas-
cularization (TLR) depending on the type of stent used.12 As a
limitation, the mentioned meta-analysis included trials that differed
in terms of patient population enrolled, antiplatelet regimen, and
length of follow-up. A beneficial effect of DES in DM was con-
firmed in large prospective registry of consecutive patients allow-
ing for a comparison of two propensity-matched cohorts of
1476 patients each undergoing DES or BMS implantation.13 The
3-year risk-adjusted mortality, MI, and TVR rates in the DES vs.
BMS propensity matched cohorts were 17.5 vs. 20.7% (P ¼
0.02), 13.8 vs. 16.9% (P ¼ 0.02), and 18.4 vs. 23.7% (P, 0.001),
respectively.
Most of the large-scale clinical investigations showed that the
DES thrombosis rate was higher in DM than in non-DM patients
and on several occasions DM was identified as independent predic-
tor of stent thrombosis (Figure 2). This observation, together with
the marked reduction in this complication associated with potent
platelet inhibitors such as prasugrel and ticagrelor, supports the
notion that the prothrombotic state and the impaired response
to dual antiplatelet therapy observed in DM patients are clinically
relevant.14,15
Differences among drug-eluting stents
In vitro studies have suggested that, due to different signalling path-
ways, sirolimus may be less effective than paclitaxel in the inhibition
of smooth muscle cell migration and survival in an environment
Figure 2 Studies having detected diabetes mellitus or insulin-dependent diabetes mellitus as independent predictor of drug-eluting stent
thrombosis. Reported are the hazard ratio or odds ratio of multivariable analyses. Data extracted from Iakovou et al.,65 Urban et al.,66
Kuchulakanti et al.,67 Machecourt et al.,10 Daemen et al.,68 de la Torre et al.,69 and Urban et al.70
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mimicking DM state.16 However, a meta-analysis of five
head-to-head studies dedicated to DM patients (n ¼ 1173)
demonstrated that the sirolimus-eluting Cypher (Cordis) stent
was more effective than the paclitaxel-eluting stent Taxus
(Boston Scientific) with respect to TLR (5.1 vs. 11.4%; OR 0.41,
P, 0.001) and angiographic binary restenosis (5.6 vs. 16.4%; OR
0.30, P, 0.001). A subgroup analysis of the DM population (n ¼
414) of the head-to-head trial comparing the biolimus-eluting
stent Biomatrix (Biosensor) and the Cypher stent showed no
difference in death, MI, or TVR at 9 months.17 With respect to
the everolimus-eluting stent Xience (Abbott), the SPIRIT V registry
showed a low rate of death, MI, and TVR at 1 year (6.8%) in 2700
patients and the outcomes of the DM subgroup (30% of the popu-
lation) did not significantly differ from the overall study results.18 A
head-to-head trial allocating patients to the Xience or the Taxus
stent showed low target lesion failure at 1 year in the DM popu-
lation (n ¼ 1185) without differences between the groups (6.4
vs. 6.9%, respectively).19 Based on current data, none of the DES
can be singled out as the device of choice for DM patients.
Coronary artery bypass surgery
In analogy to what observed in PCI, DM negatively affects the out-
comes of CABG. A retrospective analysis of the Society of Thor-
acic Surgery database including 41 663 DM patients among a total
population of 146 786 patients showed that the 30-day CABG
mortality was significantly increased in DM compared with
non-DM individuals (adjusted OR: 1.2).20 Patients on insulin had
the highest mortality rate (adjusted OR: 1.4). In addition, the
overall morbidity and the infection rates were significantly elevated
in DM patients. Finally, a study on 440 patients undergoing CABG
and mandating angiographic follow-up at 1 year identified DM as
independent predictor of graft occlusion (RR: 1.45).21
A recent randomized study comparing saphenous vein and radial
grafting in addition to single internal mammary artery (IMA) bypass
suggested that in DM patients (n ¼ 307) patency of radial grafts
was inferior to saphenous veins, while the opposite was true for
non-DM patients (n ¼ 450).22 The Arterial Revascularisation
Trial (ART) trial randomized 3102 patients to single vs. bilateral
IMA with a primary outcome of survival at 10 years.23 Mortality
at 30 days and 1 year as well as the rates of stroke, MI, and
repeat revascularization were similar between the two groups.
Sternal wound reconstruction for infection was more frequent in
the bilateral IMA group. While no outcome data for the DM sub-
group (n ¼ 734) are available, it is notable that DM patients suf-
fered half of all sternal wound reconstructions for infection
although they accounted for only 24% of the studied population.
At this time it is unknown whether the increased risk of sternal
wound infection associated with bilateral IMA grafting in DM
patients will be counterbalanced by a long-term benefit.24 The
risk of impaired wound healing may be minimized by avoiding bilat-
eral IMA grafts in obese DM patients and by modification of the
IMA dissection technique. Accordingly, IMA ‘skeletonization’ (i.e.
only the IMA is harvested) rather than ‘pedicled IMA harvesting’
(i.e. the IMA and the surrounding tissue are harvested) may pre-
serve collaterals and sternal blood supply and may improve
wound healing, particularly in DM patients.25 Nevertheless, in a
series of 1515 consecutive patients undergoing skeletonized IMA
harvesting DM remained an independent predictor of sternal infec-
tion (OR: 4.6 and 6.9 for DM patients on oral hypoglycaemic drugs
and insulin, respectively).26
Percutaneous vs. surgical
revascularization
A pooled analysis of individual patient data from 10 randomized
trials compared the effectiveness of CABG with angioplasty or
BMS-based PCI in 7812 patients with multivessel CAD over a
median follow-up of 5.9 years.27 While among non-DM patients
no difference in mortality between CABG and PCI was observed,
in patients with DM (CABG, n ¼ 615; PCI, n ¼ 618), mortality was
lower in the surgical group (23%) than in the PCI group (29%) (HR
¼ 0.70, 0.56–0.87) (Figure 3).27 Within a statewide registry, the
outcomes of DM patients with multivessel disease treated with
CABG (n ¼ 2844) did not differ from those undergoing DES-based
PCI (n ¼ 3256) with respect to the adjusted rate of death (HR ¼
0.97, P ¼ 0.75) and death or MI (HR ¼ 0.84, P ¼ 0.07).28 In the
Arterial Revascularization Therapy Study (ARTS)-I study patients
were randomized to treatment with a BMS or CABG, whereas
in the single-arm ARTS-II study, with similar inclusion criteria,
patients underwent DES-based PCI. Among the DM patients
included, no difference was observed in terms of mortality or MI
between the ARTS-I CABG group (n ¼ 96) and the ARTS-II DES
group (n ¼ 159) but CABG was associated with a lower risk of
repeat revascularization (10.7 vs. 33.2%; P, 0.001).29
The SYNergy between percutaneous coronary intervention
with TAXus and cardiac surgery (SYNTAX) study randomly
assigned 1800 patients (452 with DM) to receive Taxus stents or
Figure 3 Mortality in patients assigned to coronary artery
bypass graft or percutaneous coronary intervention by diabetes
status in an analysis of 10 randomized trials. Reproduced with
permission from Hlatky et al.27
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CABG. The pre-specified DM-subgroup analysis showed that,
driven by an increased rate of repeat revascularization, the
1-year death, stroke, MI, or repeat revascularization rate was sig-
nificantly higher among DM patients treated with DES than with
CABG while no difference between the groups was observed in
the rate of death, stroke, or MI (Table 1).30 The mortality rate
was higher after PCI (13.5%) than after CABG (4.1%, P ¼ 0.04)
in DM patients with highly complex lesions (i.e. SYNTAX score
≥33), in those with the lowest SYNTAX score tertile the 1-year
death, stroke, MI, or repeat revascularization rate did not differ
between CABG and PCI (18.3 vs. 20.3%). These findings suggest
that the complexity of CAD rather than DM status should be con-
sidered in CABG vs. PCI decision-making. The CARDia (Coronary
Artery Revascularization in Diabetes) Trial compared PCI (1/3
BMS and 2/3 DES) and CABG in 510 DM patients with multives-
sel CAD. At 1 year, the primary endpoint of death, MI, and stroke
did not differ among the groups while the need of repeat revascu-
larization was significantly higher in the PCI group (Table 1).31
Overall, CABG should be considered superior to angioplasty or
BMS-based PCI in DM patients with multivessel disease both in
terms of MACE and late mortality. In the era of first-generation
DES, based on the results of the CARDia and SYNTAX trials, it
can be stated that at 1-year DM patients treated with PCI or
CABG have similar mortality rates as well as a similar rate of the
composite of death, MI, or stroke. However, the risk of repeat
revascularization remains substantially higher for DM patients
undergoing PCI compared with those undergoing CABG. Finally,
potential long-term advantages of CABG over PCI include the
more complete revascularization and the protection against
disease progression in native coronary segments proximal to the
anastomosis site.
For the individual DM patient, multiple parameters should be taken
into account for the choice of revascularization strategy, such as clini-
cal presentation [acute coronary syndrome (ACS) vs. stable CAD],
coronary anatomy, ischaemic burden, previous cardiac surgery, left
ventricular function, co-existing comorbidities, and patient
preference (Figure 4). The recent European myocardial revasculariza-
tion guidelines recommend revascularization in all stable DM patients
with extensive CAD (Class I, level of evidence A).32 In addition, in DM
patients they consider CABG rather than PCI when the extent of the
CAD justifies a surgical approach and the patient’s risk profile is
acceptable (Class IIa, level of evidence B). This consensus document
strongly promotes a multidisciplinary approach (‘heart team’) as the
way to guarantee that all therapeutic options (i.e. optimal medical
therapy, PCI, and CABG) are transparently discussed.
Medical management vs.
revascularization
Stable coronary artery disease
Until recently, little if any data were available on revascularization
vs. medical management in DM patients with stable CAD.33 The
Bypass Angioplasty Revascularization Investigation (BARI) 2D trial
randomly assigned 2368 DM patients with stable CAD to either
prompt revascularization with intensive medical therapy or inten-
sive medical therapy alone.34 Primary end points were the 5-year
rate of death and of MACE defined as a composite of death, MI,
or stroke. Randomization was stratified according to the choice
of PCI or CABG as the more appropriate intervention. Survival
as well as MACE did not differ between the two groups
(Figure 5). At 5 years, 42% of patients randomized in the conserva-
tive arm crossed over to revascularization. With respect to sub-
groups, while in the PCI stratum there was no significant
difference in the primary end points between the revascularization
group and the medical therapy group, in the CABG stratum the
MACE rate was significantly lower in the revascularization group
(22.4%) than in the medical therapy group (30.5%, P ¼ 0.01; P ¼
0.002 for interaction between stratum and study group).34 Impor-
tantly, the CABG stratum included patients with a higher risk
profile. Therefore, no conclusion should be drawn on the efficacy
of PCI vs. CABG based on those results. Overall, the BARI 2D trial
shows that in DM patients with stable CAD and no high-risk
features on coronary angiography medical therapy may be a
valuable initial strategy.
Acute coronary syndromes
Diabetic patients with ACS have worse outcomes than non-DM
counterparts. A pooled analysis of several ACS trials including 46
577 STEMI and 15 459 non-ST-ACS patients showed that 30-day
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 One-year events in the diabetic subgroup of SYNTAX trial and in the CARDIa trial
SYNTAX (n 5 452) CARDIa (n5 510)
CABG (n5 221)
(%)
PCI (n 5 231)
(%)
P-value CABG (n 5 248)
(%)
PCI (n5 254)
(%)
P-value
Death 6.4 8.4 0.43 3.2 3.2 0.97
MI 4.4 4.8 0.83 5.7 9.8 0.088
Stroke 2.5 0.9 0.26 2.8 0.4 0.066
Repeat revascularization 6.4 20.3 ,0.001 2.0 11.8 ,0.001
Death/MI/stroke 10.3 10.1 0.96 10.5 13.0 0.393
Death/MI/stroke repeat revascularization 14.2 26.0 0.003 11.3 19.3 0.016
Data extracted from refs30,31.
MI, myocardial infarction.
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mortality was significantly higher among DM patients both in the
setting of non-ST-ACS (2.1 vs. 1.1%, P, 0.001) and STEMI (8.5
vs. 5.4%, P, 0.001), with an adjusted risk of death of 1.8 and
1.4, respectively.35 The increased mortality risk persisted at 1
year (HR ¼ 1.7 and 1.2, respectively). Regarding the efficacy of
early invasive strategy in non-ST-ACS, the Fragmin and Fast Revas-
cularisation during InStability in Coronary artery disease (FRISC II)
study detected a more pronounced benefit among DM (n ¼ 299)
than non-DM individuals both in terms of relative (39 vs. 28%) and
absolute (9.3 vs. 3.1%) risk reduction for death or MI at 1 year.36
Similarly, in the Treat Angina with Aggrastat and Determine Cost
of Therapy with an Invasive or Conservative Strategy
(TACTICS)-TIMI 18 trial, DM patients (n ¼ 296) derived a
greater benefit than non-DM individuals from an early invasive
strategy both in terms of relative (27% and 13%, respectively)
and absolute (7.6 and 1.8%, respectively) reduction in 6-month
death, MI, or rehospitalisation for ACS.37
The Euro Heart Survey on Diabetes and the Heart recruited 3488
patients (2063 non-DM and 1425 DM) patients with CAD and fol-
lowed them for 1 year.38 The population consisted of approximately
one-third of stable and two-thirds of unstable CAD patients. While
revascularization was of no benefit in non-DM patients, it signifi-
cantly reduced mortality (5.7 vs. 8.6%) and the rate of death, MI,
or stroke (9.9 vs. 16.9%) in DM patients (Figure 6). In addition, a stat-
istically significant interaction between DM status and effect of revas-
cularization was observed, suggesting a preferential benefit from
revascularization for DM patients.38 While the American ACS guide-
lines consider that decision-making with respect to stress testing,
angiography, and revascularization should be similar in patients
with and without DM, the European ones recommend an early inva-
sive strategy for all DM patients presenting with ACS.39,40
Antiplatelet therapy
Numerous investigations have shown that the platelet hyper-
reactivity observed in DM patients persists under single and dual
Figure 4 Parameters guiding the choice of revascularization strategy in diabetic patients. STEMI, ST-elevation myocardial infarction; ACS,
acute coronary syndromes; CAD, coronary artery disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary interventions;
STS, Society of Thoracic Surgery. Modified with permission from Roffi and Brandle.71
Figure 5 Freedom from major cardiovascular events, revascu-
larization vs. medical therapy at 5 years in the BARI 2D trial.
Reproduced with permission from Frye et al.34
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antiplatelet treatments, a phenomenon also coined as ‘resist-
ance’.41,42 The latter may contribute to their higher rates of recur-
rent atherothrombotic events observed in DM patients with ACS
or undergoing PCI. Three classes of antiplatelet agents have been
approved for the prevention and treatment of coronary events:
aspirin, adenosine diphospate (ADP) P2Y12 receptor antagonists,
and GP IIb/IIIa inhibitors.
Aspirin
Aspirin selectively and irreversibly acetylates the cycloxigenase-1
(COX-1) enzyme, thereby blocking platelet formation of throm-
boxane A2 (TXA2). In the primary prevention setting, two random-
ized trials focusing on DM patients were not able to show a benefit
from aspirin over placebo.43,44 The use of low-dose aspirin (75–
162 mg/day) for secondary prevention is supported by large
meta-analyses, the results of which have been extended to patients
with DM.45 The lack of benefit and the potential for increased
bleeding complications of high (300–325 mg) vs. low-dose (75–
100 mg) aspirin was recently demonstrated in the CURRENT/
OASIS-7 (Clopidogrel optimal loading dose Usage to Reduce
Recurrent EveNTs-Organization to Assess Strategies in Ischemic
Syndromes) trial, but no data on DM is available.46
Several studies have shown an association between aspirin
resistance and a higher risk of recurrent ischaemic events.47
Aspirin resistance has been described in DM and hyperglycaemia
is believed to play an important role in the process via the
increased protein glycation with subsequent decrease in aspirin-
mediated protein acetylation and reduced sensitivity of platelets
to aspirin.48 In addition, poor DM control and the increased plate-
let turnover rate described in DM have been associated with an
increase in TXA2 synthesis.
49 Preliminary data suggest that in
DM twice daily aspirin regimen, rather than an increase in dose,
may be more effective in inhibiting newly generated platelets
released into the circulation.50
Clopidogrel
The platelet ADP P2Y12 receptor plays a central role in platelet
activation and aggregation processes. Thienopyridines (i.e.
Figure 6 Kaplan–Meier curves on survival comparing patients
with and without diabetes who were revascularized or not in the
Euro Heart Survey on Diabetes. Reproduced with permission
from Anselmino et al.38
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ticlopidine, clopidogrel, and prasugrel), are non-direct (i.e. metab-
olism required), orally administered, and irreversible platelet P2Y12
receptor inhibitors. In patients with stable atherosclerotic disease
not requiring PCI, dual antiplatelet therapy was of no benefit
over aspirin in the CHARISMA (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, and
Avoidance) trial, in which 42% (n ¼ 6555) of the overall study
population had DM.51 In the setting of ACS/PCI, the recommen-
dation for dual antiplatelet therapy with aspirin and clopidogrel is
supported by numerous clinical trials. Of note, despite the
higher baseline risk of DM patients, the benefit of dual antiplatelet
therapy over aspirin alone was not more pronounced than in the
non-DM individuals (Table 2). The somehow disappointing efficacy
of dual antiplatelet therapy in DM has been attributed to the high
on-treatment platelet reactivity (‘clopidogrel resistance’) observed
in DM, especially at its most advanced stage.42
The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes
Mellitus) study evaluated the effect of a 150 vs. 75 mg maintenance
dose of clopidogrel in DM patients with high platelet reactivity. The
150 mg maintenance dose was associated with a marked increase
in platelet inhibition but a suboptimal clopidogrel response was
still present in over half of the patients.52 In the subgroup of
patients undergoing PCI (n ¼ 17 232) of the CURRENT/OASIS-7
trial, a study comparing 600 mg loading dose of clopidogrel
followed by 150 mg/day for 6 days and 75 mg/day beyond that
to 300 mg loading dose followed by 75 mg/day, high clopidogrel
dose regimen significantly reduced ischaemic events as well as
the risk of stent thrombosis at 30 days. However, no difference
in ischaemic events was observed among DM patients
(n ¼ 3844) (Figure 7).53
Prasugrel
Prasugrel, a third-generation thienopyridine, is a prodrug requiring
hepatic metabolism to give origin to the active metabolite which
irreversibly inhibits the P2Y12 receptor.
54 This compound has a
more rapid onset of action than clopidogrel and provides greater
platelet inhibition due to its more effective conversion into the
active metabolite. In the TRITON-TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction
38) trial, prasugrel compared with clopidogrel significantly
reduced the primary end point of cardiovascular death, MI, or
stroke (9.9 vs. 12.1%; HR ¼ 0.81; P, 0.001) in patients (n ¼
13 608) with moderate to high-risk ACS undergoing PCI over a
period of 15 months.55 A significant reduction in the stent throm-
bosis rate associated with the use of prasugrel was also observed.
However, the benefit was hampered by an increased risk of TIMI
major non-CABG related bleeding in the prasugrel group (2.4 vs.
1.8%; P ¼ 0.03). The reduction in the primary endpoint with prasu-
grel observed in subjects with DM (12.2 vs. 17.0%; HR ¼ 0.70; P,
0.001) was even more pronounced than in non-DM individuals (9.2
vs. 10.6%; HR ¼ 0.86; P ¼ 0.02). The benefit was consistent in
patients without (11.5 vs. 15.3%; HR ¼ 0.74; P ¼ 0.009) and with
(14.3 vs. 22.2%; HR ¼ 0.63; P ¼ 0.009) insulin treatment.14 Myo-
cardial infarction was reduced by 18% with prasugrel among sub-
jects without DM (7.2 vs. 8.7%; P ¼ 0.006) and by 40% among
subjects with DM (8.2 vs. 13.2%; P, 0.001). In the interaction
analyses for treatment benefit, diabetic status showed a trend (P
¼ 0.09) for the primary endpoint and was significant (P ¼ 0.02)
for MI, suggesting a preferential benefit of prasugrel in the DM
population. Importantly, there were no differences in major bleed-
ings among DM patients treated with prasugrel and clopidogrel
(2.6 vs. 2.5%). Prasugrel therapy also dramatically reduced stent
thrombosis rates compared with clopidogrel in DM patients
(overall DM cohort: 2.0 vs. 3.6%; HR ¼ 0.52; P ¼ 0.007; insulin-
treated patients: 1.8 vs. 5.7%; HR ¼ 0.31; P ¼ 0.008).14 Such
enhanced clinical benefit observed in DM patients may be
explained by its greater platelet inhibitory effects even compared
with double-dose clopidogrel, as shown in the OPTIMUS-3
study.56
Ticagrelor
Ticagrelor, a first in class cyclopentyltriazolopyrimidine, is an orally
administered, direct-acting (i.e. no metabolism is required) and
reversible P2Y12 inhibitor with more prompt and potent platelet
inhibitory effects than clopidogrel. The PLATO (Platelet Inhibition
and Patient Outcomes) trial showed that ticagrelor compared with
clopidogrel (300–600 mg) loading significantly reduced the rate of
the primary ischaemic endpoint of death from vascular causes, MI
or stroke at 12 months (10.2 vs. 12.3%; HR ¼ 0.84; P ¼ 0.0001) in
ACS patients (n ¼ 18 624) treated either medically or undergoing
revascularization (percutaneous or surgical).57 There was also a
reduction in the rate of cardiovascular death (4.0 vs. 5.1%; HR ¼
0.79; P ¼ 0.001) and the occurrence of definite/probable stent
thrombosis (2.2 vs. 2.9%; HR ¼ 0.75; P ¼ 0.02) in the subgroup
of patients undergoing PCI. Importantly, ticagrelor was not associ-
ated with an increase on protocol-defined major bleeding (11.6 vs.
11.2%; HR ¼ 1.04; P ¼ 0.43), although a higher rate of major
bleeding not related to CABG was observed (4.5 vs. 3.8%; HR ¼
1.19; P ¼ 0.03). In a predefined subgroup analysis of the DM
cohort (n ¼ 4662), the reduction in the primary ischaemic end-
point (HR ¼ 0.88; 95% CI, 0.76–1.03), all-cause mortality (HR ¼
0.82; 95% CI, 0.66–1.01), and stent thrombosis (HR ¼ 0.65; 95%
CI ¼ 0.36–1.17) in the absence of an increase in major bleeding
(HR ¼ 0.95; 95% CI ¼ 0.81–1.12) with ticagrelor was consistent
with the overall results.15 A summary of the efficacy of novel strat-
egies to enhance platelet inhibition in DM patients with ACS is
reported in Figure 7.
Glycoprotein IIb/IIIa inhibitors
Currently, three intravenous GP IIb/IIIa inhibitors (abciximab, epti-
fibatide, and tirofiban) are approved for clinical use in the PCI/ACS
setting.58 The introduction of novel antiplatelet treatments
described above have led to a reduced utilization of these agents
in clinical practice.59 A meta-analysis of six large randomized
ACS trials evaluating the effect of GP IIb/IIIa inhibitors in the
absence of systematic clopidogrel use observed a mortality
benefit at 30 days in DM patients, particularly those undergoing
PCI, associated with the use of these agents.60 However, the
ISAR-SWEET (Intracoronary Stenting and Antithrombotic
Regimen: Is Abciximab a Superior Way to Eliminate Elevated
Thrombotic Risk in Diabetics) trial did not show a benefit of abcix-
imab over placebo on the 1-year risk of death and MI in DM
patients undergoing elective PCI after pretreatment with a
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600 mg clopidogrel loading dose.61 Therefore, these results do not
support the routine use of GP IIb/IIIa inhibitors in elective PCI in
DM patients. On the contrary, the ISAR-REACT 2 (Intracoronary
Stenting and Antithrombotic: Regimen Rapid Early Action for Cor-
onary Treatment 2) trial showed a significant reduction in ischae-
mic events at 30 days with abciximab treatment in patients with
high-risk ACS undergoing PCI pretreated with 600 mg of clopido-
grel.62 This benefit, however, was restricted to patients with elev-
ated troponin levels and was observed across all subgroups,
including DM patients. These results support the use of GP IIb/
IIIa receptor antagonists in high-risk ACS patients undergoing
PCI, in particular those with DM. A recent meta-regression analysis
of randomized trials showed that GP IIb/IIIa inhibitors in STEMI
patients treated with primary PCI to be associated with a benefit
in terms of death, but not re-infarction, in high-risk patients, includ-
ing those with DM.63 An emerging alternative to the combination
of GP IIb/IIIa inhibitors and unfractionated heparin in DM patients
with ACS is bivalirudin monotherapy, showing similar ischaemic
benefit and reduced bleeding risk.64
Future perspectives
Promising antiplatelet strategies include the thromboxane (TP)
receptor inhibitors ramatroban and Si8886/terutroban; the com-
bined TXA2 synthase inhibitors and TP receptor blockers picota-
mide and ridogrel; and NCX 4016, a NO-releasing aspirin
derivative. In addition, several drugs have been suggested to be
used as an adjunctive treatment to aspirin and P2Y12 inhibitors,
leading to the so called ‘triple therapy’, namely cilostazol;
protease-activated receptor-1 antagonists (vorapaxar or
SCH530348 and atopaxar or E5555); and new oral anticoagulants
including anti-factor IIa (e.g. dabigatran) and anti-factor Xa (e.g.
rivaroxaban, apixaban). From a device perspective, there is great
hope that bioresorbable stents may be the solution to overcome
many if not all limitations of metallic stents. Surgical outcomes
may further improve by wide implementation of arterial revascu-
larization, reduction in perioperative stroke by avoiding clamping
of the aorta, reduction in wound infection by minimally invasive
techniques and optimization of post-operative medical treatment.
Clinical recommendations
While an aggressive cardiovascular prevention strategy and ade-
quate blood glucose control remain cornerstones of the manage-
ment of DM patients, the decision when and how to proceed to
coronary revascularization should be based on multiple par-
ameters including clinical presentation, coronary anatomy, ischae-
mic burden, left ventricular function, and comorbidities. All DM
patients with complex multivessel CAD should be discussed
within a heart team, consisting of cardiologists, cardiac surgeons,
and anaesthesiologists. Overall, the threshold for CABG should
be lower in DM patients than in non-DM individuals. In DM
patients undergoing PCI, the use of DES is recommended while
in ACS, an early invasive strategy and a broad use of potent platelet
inhibitors such as prasugrel and ticagrelor should be favoured.
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